Clinical Trial Update: Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating radiotherapy with pembrolizumab for metastatic head and neck squamous cell carcinoma; the study was terminated and results have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of Erlangen-Nürnberg Medical School | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2026-03-12